Retatrutide's Timeline to Market: What We Know About FDA Approval

Retatrutide is the most anticipated weight loss drug since semaglutide. Developed by Eli Lilly, it targets three receptors (GLP-1, GIP, glucagon) and has produced weight loss of up to 28.7% in Phase 3 trials — approaching bariatric surgery territory without the scalpel.

But when will it actually be available? This article traces the regulatory timeline, the remaining hurdles, and what fitness professionals should expect.

Where We Are Now

As of April 2026:

• Phase 2 trial: Complete. Published in NEJM (2023). Showed up to 24.2% weight loss over 48 weeks.
• Phase 3 TRIUMPH-4 (obesity): Results reported December 2025. 28.7% weight loss over 68 weeks.
• Phase 3 TRANSCEND-T2D-1 (type 2 diabetes): Results reported March 2026. 16.8% weight loss over 40 weeks.
• Seven additional Phase 3 trials: Ongoing through 2026, covering knee osteoarthritis, sleep apnea, cardiovascular outcomes, and additional diabetes/obesity populations.

The Regulatory Path Forward

Step 1: Complete the Phase 3 program (ongoing) Eli Lilly needs sufficient Phase 3 data to support the New Drug Application (NDA). TRIUMPH-4 and TRANSCEND-T2D-1 provide the primary data. The remaining trials expand the label (additional indications, longer-term safety data).

Step 2: NDA Submission (expected Q4 2026 or Q1 2027) Eli Lilly will submit the NDA to the FDA. The submission includes all clinical trial data, manufacturing information, proposed labeling, and safety analyses. This is typically a massive document — thousands of pages.

Step 3: FDA Review (6-10 months standard, 6 months priority) Once the NDA is accepted, the FDA has a defined review period. For drugs with breakthrough therapy designation (which retatrutide may receive given its unprecedented efficacy), the review can be faster.

Step 4: Advisory Committee (optional) The FDA may convene an advisory committee of external experts to review the data and make a recommendation. This is common for first-in-class drugs and those with novel safety concerns.

Step 5: FDA Decision The FDA issues a Complete Response Letter (approval) or a request for additional data. If approved, the drug can be marketed.

Step 6: DEA Scheduling (if applicable) Because retatrutide is an injectable peptide, DEA scheduling is typically straightforward and doesn't add significant delay.

Realistic Timeline

• NDA submission: Late 2026 or early 2027
• FDA decision: Mid to late 2027 (standard review) or early 2027 (priority review)
• Market availability: Late 2027 (US), 2028-2029 (international)

Eli Lilly's CEO has publicly indicated that the company is targeting the "soonest possible" submission, suggesting they will not wait for all Phase 3 trials to complete before filing.

Pricing and Access

Based on current GLP-1 pricing:

• Semaglutide (Wegovy): ~$1,350/month list price
• Tirzepatide (Zepbound): ~$1,060/month list price
• Retatrutide: Likely $1,000-1,500/month at launch

Insurance coverage will depend on label indication. If approved for obesity (not just diabetes), coverage may be broader than current GLP-1s — but this depends on ongoing policy changes.

Manufacturing Scale

One significant hurdle: peptide manufacturing at scale. Retatrutide requires more complex manufacturing than semaglutide (triple agonist vs. single). Eli Lilly has invested heavily in manufacturing capacity, but supply constraints at launch are likely — similar to the Wegovy and Zepbound shortages experienced in 2024-2025.

What Trainers Should Do Now

1. Educate yourself. Retatrutide will change the weight loss landscape when it arrives. Understanding the mechanism and implications now prepares you for client questions.

2. Develop GLP-1 programming protocols. The programming principles for retatrutide are the same as for semaglutide and tirzepatide — just more intense. Build your GLP-1 client programming framework now.

3. Prepare for the body composition conversation. Clients on retatrutide will lose weight dramatically. Helping them preserve muscle and maintain functional fitness will be your primary value proposition.

References

1. Jastreboff et al. (2023). NEJM, 389(6), 514-526. DOI: 10.1056/NEJMoa2301972
2. TRIUMPH-4 Results. Eli Lilly (December 2025).
3. TRANSCEND-T2D-1 Results. Eli Lilly (March 2026).
4. FDA Drug Approval Process. FDA.gov.
5. Eli Lilly Q4 2025 Earnings Call — retatrutide timeline commentary.

This article is for informational purposes only and does not constitute medical advice.